LivaNova PLC (LIVN)

NMS – Real Time Price. Currency in USD

83.43

+2.38 (2.94%)

At close: Jun 26, 2026, 4:00 PM EDT

83.43

-0.00 (-0.00%)

After-hours: Jun 26, 2026, 4:36 PM EDT

16.06.2026

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when treated with proximal hypoglossal nerve stimulation (pHGNS). The findings were presented at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societie.

11.06.2026

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors after its Annual General Meeting of shareholders on June 10. “We're pleased to welcome Jette to LivaNova's Board,” said William Kozy, Chair. “She brings deep medtech governance expertise, proven CEO leadership, and a strong track record of transformation, strategic M&A, and digital innovation across complex gl.

10.06.2026

LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript

08.06.2026

LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

05.06.2026

LivaNova Appoints Anne Liddy as Chief Legal Officer

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company's global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins LivaNo.

21.05.2026

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Tea.

19.05.2026

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be.

Videos

No Data

There is no data to display

Press releases

16.06.2026

LivaNova PLC (LIVN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

LivaNova PLC (LIVN)

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript

LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

Videos

No Data

Press releases

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript

LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

Videos

No Data

Press releases

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

Search stocks

LivaNova PLC (LIVN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

LivaNova PLC (LIVN)

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript

LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

Videos

No Data

Press releases

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript

LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

Videos

No Data

Press releases

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit